Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04867720
Status:
UNKNOWN
Last Update Posted:
2021-04-30
First Post:
2021-04-29
Brief Title:
Efficacy and Safety of CertiroBell Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients
Sponsor:
Chong Kun Dang Pharmaceutical
Organization:
Chong Kun Dang Pharmaceutical
Study Overview
Official Title:
Multi-center Single Arm Open-label Phase 4 STudy to Evaluate the Efficacy and Safety of CertiroBELL Tablet Plus TAcrolimus in Primary Living Donor Liver Transplant Recipients
Status:
UNKNOWN
Status Verified Date:
2021-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STELLA
Brief Summary:
To evaluate the efficacy and safety of CertiroBell tablet plus tacrolimus
Detailed Description:
This study is multi-center single arm open-label phase 4 study to evaluate the efficacy and safety of CertiroBell tablet plus tacrolimus in primary living donor liver transplant recipients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None